 |
Medscape Conference Coverage, based on selected sessions at the: American Society of Hematology (ASH) 49th Annual Meeting and Exposition December 8 - 11, 2007, Atlanta, Georgia This activity is not sanctioned by, nor a part of, the American Society of Hematology.
Topic OverviewsExpert InterviewConference News- Intensive Regimen May be Curative in Mantle Cell LymphomaAn intensive immunochemotherapy regimen used in a Nordic study shows a plateau in survival curves that suggest a cure is in sight, say researchers.
Medscape Medical News, December 19, 2007 - Oblimersen with Chemotherapy Improves Survival in with Relapsed CLLThe addition of the antisense agent oblimersen to fludarabine and cyclophosphamide improved response to therapy and survival in patients with relapsed or refractory chronic lymphocytic leukemia.
Medscape Medical News, December 19, 2007 - Addition of Bortezomib Improves Remission in Multiple MyelomaAdding bortezomib to standard induction therapies in patients with newly diagnosed multiple myeloma improves complete remission rates.
Medscape Medical News, December 18, 2007 - Mutation in JAK2 Associated with ALL in Children with Down SyndromeMutations in the JAK2 gene appear to be associated with nearly 20% of cases of acute lymphoblastic leukemia in children with Down syndrome.
Medscape Medical News, December 14, 2007 - Novel Vaccine Improves Event-Free Survival in Myeloid Leukemia PatientsAn experimental peptide vaccine produced an immunologic response in more than half of study participants and was associated with longer event-free survival and periods of remission.
Medscape Medical News, December 13, 2007 - Combination Imatinib and Chemotherapy Improves Survival in Children with Ph-Positive ALLCombining a tyrosine kinase inhibitor with intensive chemotherapy doubled the survival rate in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Medscape Medical News, December 13, 2007 - Plerixafor Improves Stem Cell Harvests for TransplantationA novel product mobilizes stem cells quickly and increases the yield, making stem cell transplantation a viable option for more patients.
Medscape Medical News, December 13, 2007 - Complete Remission in Acute Myeloid Leukemia with Novel Antibody LintuzumabAn experimental antibody produced complete remissions in elderly patients with acute myeloid leukemia.
Medscape Medical News, December 13, 2007 - Unrelated Cord Blood Transplant Improves Survival in Fatal Congenital DiseasesInfants with lysosomal and peroxisomal disorders (LSD), such as Krabbe disease and Hurler syndrome, which are often fatal, can be managed with umbilical cord blood transfusions from unrelated donors.
Reuters Health, December 13, 2007 - Challenge to Standard Care in Advanced-Stage Hodgkin's LymphomaNew results with an escalated chemotherapy regimen challenge the standard treatment for advanced-stage Hodgkin's lymphoma.
Medscape Medical News, December 12, 2007 - New Data Look Promising for RivaroxabanTwo phase 3 trials with the new oral anticoagulant rivaroxaban suggest it is more effective than enoxaparin in preventing venous thromboembolism in patients undergoing major orthopedic surgery.
Heartwire, December 12, 2007 - Investigational Agent Eliminates Resistance in CMLA new Abl kinase inhibitor that eliminates resistance to nilotinib and dasatinib in the treatment of chronic myeloid leukemia (CML) in mice and in human cell lines was described this week at the 49th annual meeting of the American Society of Hematology in Atlanta, Georgia.
Reuters Health, December 12, 2007 - Rates of Thromboembolism Prophylaxis in Surgical Patients InadequateOverall, about 85% of surgical patients do not receive recommended venous thromboembolism (VTE) prophylaxis, researchers reported at the 49th annual meeting of the American Society of Hematology in Atlanta, Georgia.
Reuters Health, December 12, 2007 - Umbilical Cord Blood is a Viable Source of Stem Cells for Older PatientsUmbilical cord blood can be an alternative graft source for older patients in need of a hematopoietic stem cell transplant, but who lack an HLA-matched related donor.
Medscape Medical News, December 11, 2007 - Zevalin Improves Progression-Free Survival by 2 Years in Follicular LymphomaDramatic results showing that radioimmunotherapy with Zevalin prolongs progression-free survival by 2 years come just days after cuts in reimbursement for this therapy were announced in the United States.
Medscape Medical News, December 11, 2007 - Azacitidine is First Drug to Prolong Survival in High-Risk Myelodysplastic SyndromesFor the first time, a significant prolongation of survival has been seen in this disorder, leading to calls for azacitidine to be offered to all high-risk patients.
Medscape Medical News, December 11, 2007 - Survival Benefit with Low-Dose Dexamethasone in Multiple MyelomaUsing low-dose dexamethasone with lenalinomide instead of high-dose dexamethasone in newly diagnosed multiple myeloma patients confers a significant survival advantage and has less toxicity.
Medscape Medical News, December 11, 2007 - Dasatinib Effective in CML Patients Resistant to ImatinibAt 2-year follow-up, dasatinib continued to demonstrate efficacy and prolong survival among patients with chronic myelogenous leukemia who are either intolerant or resistant to treatment with imatinib.
Medscape Medical News, December 11, 2007 - New Thrombin Inhibitor Superior to Enoxaparin for ThromboprophylaxisThe investigational oral direct thrombin inhibitor rivaroxaban (BAY 59-7939, Bayer HealthCare, Leverkusen, Germany) is "significantly more effective" than enoxaparin for preventing embolic complications after orthopedic surgery, according to a presentation on Sunday at the 49th annual meeting of the American Society of Hematology in Atlanta.
Reuters Health, December 11, 2007 - Novel Agent Shows Efficacy in Relapsed Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaBendamustine induced a higher rate of response in patients with relapsed indolent non-Hodgkin's lymphoma and had better clinical outcomes in patients with chronic lymphocytic leukemia than chlorambucil.
Medscape Medical News, December 10, 2007 - Recombinant Interleukin-2 May Benefit Acute Myeloid Leukemia Patients in First RemissionPreliminary data suggest that rIL-2 may be of therapeutic benefit in younger AML patients who have completed therapy and entered their first remission.
Medscape Medical News, December 10, 2007 - Anemia Drugs May Raise Blood Cancer RiskErythropoiesis-stimulating drugs may increase the risk that patients with myelofibrosis will develop leukemia, U.S. researchers said on Monday.
Reuters Health, December 10, 2007 - Amgen Study Shows Romiplostim Boosts PlateletsAmgen Inc said on Saturday that a late-stage trial of its experimental drug AMG 531 showed it boosted and sustained platelet counts in adults with chronic immune thrombocytopenic purpura.
Reuters Health, December 10, 2007
Coming Soon: Clinically Focused Topic Overviews for CME- Clinical overviews by expert physician faculty will be linked as soon as they become available.
- What's New in Multiple Myeloma Research and Treatment
Sagar Lonial, MD - Myelodysplastic Syndromes: Understanding the Biology, Pursuing Targeted Treatments
Rami Komrokji, MD
|
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Hematology. These materials and the related activity are not sanctioned by the American Society of Hematology or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2007 Medscape. |
|
|
